Wegovy HD 7.2 mg reaches US pharmacies

Novo Nordisk began shipping Wegovy HD (semaglutide) injection 7.2 mg to US pharmacies in April 2026, about a month after the FDA approved the higher dose on March 19 ^[1][3]. The company's self-pay price list puts the single-dose pen at $399 a month, compared with $349 a month for the lower-dose Wegovy pens ^[2].

The approval came through the FDA Commissioner's National Priority Voucher pilot program, making semaglutide 7.2 mg the fourth product cleared under that framework and the first GLP-1 receptor agonist ^[1]. Wegovy HD is indicated along with a reduced-calorie diet and increased physical activity for adults with obesity who have already tolerated the 2.4 mg dose for at least four weeks and for whom additional weight reduction is clinically indicated ^[3]. In other words, it is a step-up option, not a starting dose.

What the trials showed

Approval rests on the phase 3b STEP UP program. STEP UP randomized 1,407 adults with a BMI of 30 or higher and without diabetes to semaglutide 7.2 mg, 2.4 mg, or placebo, all with lifestyle intervention, for 72 weeks ^[1][3]. In the analysis assuming everyone stayed on treatment, average weight loss was 20.7% with 7.2 mg, 17.5% with 2.4 mg, and 2.4% with placebo ^[3]. In the analysis counting all patients regardless of whether they stayed on the drug, the figures were 18.8%, 15.5%, and 3.9% ^[3]. AJMC reported the higher-dose figure as 18.7% versus 3.9% for placebo, a small discrepancy with the company's 18.8% ^[1][3].

About one in three participants on 7.2 mg (31.2%) lost 25% or more of their body weight, versus 15.3% on 2.4 mg and 0% on placebo ^[3]. Baseline weight averaged 248 pounds in the 7.2 mg and placebo groups and 257 pounds in the 2.4 mg group ^[3]. Eighty-nine percent of Wegovy HD patients lost at least 5% of body weight, versus 38% on placebo ^[3].

A companion trial, STEP UP T2D, enrolled about 512 adults with obesity and type 2 diabetes. There, 7.2 mg produced 13.2% mean weight loss versus placebo, and 21.3% of patients lost 20% or more ^[1].

Side effects at the higher dose

The most common adverse reactions with Wegovy HD were nausea, vomiting, dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness, hair loss and flatulence ^[3]. Dysesthesia — an altered or uncomfortable skin sensation — stood out as more frequent at the higher dose. Events involving altered skin sensation, including sensitive skin, hyperesthesia, dysesthesia and paresthesia, were reported by 22% of the Wegovy HD group, compared with 6% on 2.4 mg and 0.3% on placebo ^[3]. In STEP UP T2D, dysesthesia specifically was reported by 18.9% on 7.2 mg, 4.9% on 2.4 mg and 0% on placebo ^[1].

Why it matters for patients

The practical question for most people is cost and access. The $399 self-pay price for Wegovy HD is $50 a month more than the $349 standard self-pay price for Wegovy pens at 0.25 mg through 2.4 mg ^[2]. Novo Nordisk's introductory offer of $199 a month applies only to the first two monthly fills of 0.25 mg and 0.5 mg for patients new to the savings program, through December 31, 2026; after that, pen prices revert to $349, or $399 for Wegovy HD ^[2]. People with commercial insurance may pay as little as $25 a month with a savings offer, subject to a maximum savings of $100 a month, and government beneficiaries such as Medicare and Medicaid enrollees are excluded from that copay card ^[2].

The four-week tolerability requirement at 2.4 mg means Wegovy HD is not a shortcut. For people who have plateaued on 2.4 mg, the higher dose offers an option within the same drug class before considering other steps such as bariatric surgery ^[1]. The trade-off is a higher rate of skin-sensation side effects and more gastrointestinal events ^[1][3].

Novo Nordisk says Wegovy HD will be available through all channels where Wegovy is sold, including more than 70,000 US pharmacies such as CVS and Costco, select telehealth providers, NovoCare Pharmacy and GoodRx ^[3]. How broadly commercial insurers and employer plans will cover the 7.2 mg dose, and whether they will require documentation of a 2.4 mg trial, is not yet known from these sources.